Rituximab (anti-CD20)

製品コードA2009 別名: IDEC-C2B8

For research use only.
Not for use in humans.

Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.

Rituximab (anti-CD20)
サイズ 価格(税別)
5mg JPY 103700
20mg JPY 211700
100mg JPY 695500

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(7)

質量管理及び製品安全説明書

Immunology & Inflammation related阻害剤の選択性比較

生物活性

製品説明 Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.
同型 Human IgG1
ターゲット
CD20 [1]
体外試験

Anti-CD20 IgG1 antibody (rituximab), induces strong antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects on CD20+ Raji cells with the EC50 at 0.0365 nM and 1.5 nM, respectively.[1]

体内試験

A number of in vivo tumor models suggest the anti-tumor activity of rituximab is dependent, at least in part, on complement[2]. Rituximab can deplete B cells for several months and, as such, could represent an effective therapy for B cell-mediated autoimmune diseases. Rituximab is now widely used in onco-haematology and is currently in development in several autoimmune diseases[3].

お薦めの試験操作(参考用のみ)

細胞試験:
  • For ADCC experiments, PBMCs were isolated from healthy human donor blood to serve as effector cells and were plated with target Raji cells at E:T ratio of 50:1 in the presence of indicated concentrations of KPL-404, anti-CD20, or isotype antibodies. Target Raji cells were labeled with calcein-AM for detection of cell lysis prior to experimental set up. Following incubation for 4 hours at 37°C in 5% CO2, supernatants from the experiment were analyzed. For CDC experiments, human complement was plated with calcein-AM labeled target Raji cells in the presence of indicated concentrations of KPL-404, anti-CD20, or isotype antibodies. Following incubation for 4 hours at 37°C in 5% CO2, supernatants from the experiment were analyzed.

動物試験:
  • Objective: To study the mechanisms of follicular lymphoma’s resistance to rituximab
    Animal Models: Female CB17 severe combined immunodeficient(SCID) mice were injected (s.c.) with rituximab-resistant lymphoma cells (derived from a human FL)
    Formulation: --
    Dosages: 10mg/kg, weekly
    Administration: i.p.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/19188155

    Objective: To investigate the therapeutic effect of rituximab in combination with L19-IL2 on B-cell malignancies
    Animal Models: CB17/lcr severe combined mmunodeficiency (SCID) mice were injected (s.c.) Ramos or DoHH-2 lymphoma cells
    Formulation: saline
    Dosages: 200 μg
    Administration: i.v.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/19005180

    Rituximab can apply to immunodeficient mice (eg: SCID mice), lymphoma cell lines and other related assays (Only for Reference)

製品説明

CAS No. 174722-31-7
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問:1:
How to store the antibody?

回答:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: Rituximab (anti-CD20)を買う | Rituximab (anti-CD20) ic50 | Rituximab (anti-CD20)供給者 | Rituximab (anti-CD20)を購入する | Rituximab (anti-CD20)費用 | Rituximab (anti-CD20)生産者 | オーダーRituximab (anti-CD20) | Rituximab (anti-CD20)化学構造 | Rituximab (anti-CD20)分子量 | Rituximab (anti-CD20)代理店